Why ResMed is more than the GLP-1 bear case
The cleanest short thesis on ResMed (NYSE: RMD) is that weight-loss drugs could shrink the obstructive sleep apnea market over time and weaken demand for PAP devices. That framing is too narrow. ResMed is not just selling initial devices into a one-time diagnosis event. It operates a broader sleep-health ecosystem built around installed devices, recurring mask and accessory replacement, and software platforms that serve care settings outside the company’s core hardware base.
Even if GLP-1 therapies change the long-term treatment landscape for some patients, the business is supported by multiple demand drivers that do not disappear overnight. Obstructive sleep apnea is not explained by obesity alone, diagnosis rates remain well below the estimated global population affected by sleep apnea, and existing PAP users continue to require ongoing supplies and support. That combination makes the current earnings engine more durable than the market’s simplest disruption narrative suggests.
The more useful investor question is not whether GLP-1s matter at all. It is whether they overwhelm ResMed’s installed-base economics, recurring consumables revenue, and software diversification quickly enough to break the company’s existing cash-flow profile. So far, reported results suggest that answer is still no
What the latest results say about masks, devices, and software demand
ResMed’s fiscal 2025 reporting showed that the business kept growing even with the GLP-1 debate hanging over the stock. Total revenue for the year ended June 30, 2025, reached roughly $5.0 billion, with the Sleep and Breathing Health segment still accounting for the majority of company revenue. That matters because it shows the core franchise remained intact rather than slipping into visible volume pressure.
Within that franchise, masks and accessories remain especially important. They are tied to the installed base of active users and therefore carry more recurring characteristics than initial device placements alone. A patient already on therapy continues to replace cushions, headgear, tubing, and masks on a regular cadence, which helps stabilize revenue even when new device demand is debated. That recurring replacement cycle is a major reason ResMed should not be valued like a one-shot hardware story.
Software adds a second layer of diversification. Through Brightree and MatrixCare, ResMed also generates subscription-style revenue from home medical equipment, post-acute, and care-management workflows. The company said SaaS revenue continued to grow in fiscal 2025 and remained a meaningful complement to the device business. That makes ResMed less exposed to a single therapy narrative than a pure PAP-device company would be.
Gross margin and operating leverage also matter here. As supply-chain pressures eased and mix benefited from higher-value masks and software revenue, the company preserved the kind of earnings quality investors would expect from a business with both consumables and software exposure rather than one driven only by new machine shipments
Why the installed base, recurring supplies, and cash generation still matter
The installed base is the heart of the bull case. Every device placed with a patient can drive years of follow-on demand for masks and accessories, which means the revenue stream attached to a new patient extends well beyond the initial hardware sale. That creates a compounding effect: new users add to the future resupply pool, while the existing base keeps generating repeat demand
Cash generation reflects that durability. ResMed has consistently converted a meaningful share of earnings into operating cash flow, which gives the company room to invest in product development, software capabilities, and shareholder returns without relying on aggressive leverage. A company with recurring supplies, subscription software, and strong free-cash-flow characteristics deserves a more nuanced framework than one built around a single clinical fear.
The balance sheet adds flexibility. ResMed has maintained a conservative enough financial profile to keep investing in connected devices, data platforms, and bolt-on software capabilities. That matters because the strategic opportunity is not only to sell therapy hardware, but also to own more of the workflow around diagnosis, equipment management, and ongoing care coordination
Research and development supports that longer view. Continued investment in connected devices, data tools, and therapy optimization can make the ecosystem more valuable over time, especially if software and patient-management capabilities deepen the bond between ResMed, providers, and end users
What investors should watch next
The most important near-term signal is masks and accessories growth. If that line keeps expanding, it suggests the installed base remains healthy and patient adherence is holding up. That would directly challenge the idea that GLP-1 adoption is already eroding the business in a material way
SaaS growth is the second major signal. Investors should watch whether Brightree and MatrixCare continue to grow at a healthy pace and whether software margins improve as scale builds. If software becomes a larger share of the mix, the overall business should look more recurring and potentially less cyclical
Management commentary on patient flow, diagnosis trends, and therapy starts will also matter. The market wants evidence on whether GLP-1 use is changing referral behavior or treatment initiation in a measurable way. So far, the reported story has been far more about long-term debate than visible near-term disruption
Finally, margin direction will tell investors whether the company’s mix and pricing discipline remain intact. Continued stability in gross margin and solid cash conversion would reinforce the idea that ResMed still has a high-quality business model even as the market argues about its long-term demand curve
Key Signals for Investors
- Fiscal 2025 revenue of roughly $5.0 billion showed the core franchise kept growing despite the GLP-1 overhang.
- Masks and accessories remain a critical recurring revenue stream because they are tied to the installed base rather than only to new device placements.
- Brightree and MatrixCare give ResMed a software revenue layer that broadens the business beyond sleep devices alone.
- Cash generation and a conservative balance sheet support continued R&D, software investment, and capital returns.
- The most important watch items are masks and accessories growth, SaaS momentum, patient-flow commentary, and margin stability.
Tags:#Medical Device#Medical Technology#RMD
